「card」の検索結果

Apply or adapt a dual-theme neo-glow control board for UI kits, design-system previews, settings surfaces, admin panels, control rooms, and dense operational interfaces. Use when Codex should build or restyle interface work with bright white or dark control surfaces, compact neumorphic cards, vertical icon rails, blue/cyan halo accents, glowing active states, luminous toggles, and a board focused on control states, inputs, and specification details.

日本語の概要は準備中です。原文の説明を表示しています。

Expert in visualizing and explaining braid theory, knot mathematics, and topological concepts for educational purposes. Use for creating interactive visualizations, explainer cards, step-wise animations, and translating abstract algebra into intuitive understanding. Activate on keywords: braid theory, knot visualization, σ notation, crossing diagrams, Yang-Baxter, topological education. NOT for general math tutoring, pure knot invariant computation, or non-educational knot theory research.

日本語の概要は準備中です。原文の説明を表示しています。

Applies game theory to multi-agent coordination protocols with advisory claims, repeated interactions, daemon-mediated correlation, and deviation penalties. Use for Nash equilibrium checks, folk-theorem cooperation analysis, correlated-equilibrium routing, and price-of-anarchy audits in strategic agent systems. NOT for consumer pricing, card-game strategy, or general microeconomics outside agent coordination.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or fixing a Content Security Policy on a real site, choosing between nonce-based and hash-based CSP, adding strict-dynamic, debugging "Refused to execute inline script" errors, deploying CSP in report-only mode first, configuring report-to / report-uri, or auditing an existing policy for unsafe-inline / unsafe-eval / wildcards. Triggers: "CSP blocks legitimate inline script", strict-dynamic, nonce-{RANDOM}, sha256-{HASH}, object-src none, base-uri none, frame-ancestors, Trusted Types, X-Content-Security-Policy obsolete, report-only vs enforced. NOT for general HTTP security headers (HSTS, COOP/COEP), Trusted Types deep dive, CORS configuration, or building a WAF.

日本語の概要は準備中です。原文の説明を表示しています。

Aligns sample metadata with count matrices and constructs design matrices for downstream DE, handling the alphabetical-reference-level trap (relevel BEFORE DESeq), LRT reduced-model rules, the interaction-term resultsNames trap, continuous-covariate scaling and splines, repeated measures via duplicateCorrelation or dream, high-cardinality categorical pseudo-singular designs, sample swap detection via XIST/RPS4Y1 expression and somalier/NGSCheckMate genotypes, SABV (sex-as-biological-variable) mandate, Simpson's-paradox collapsing of technical replicates, and the `~ 0 + group` parameterization for clean contrasts. Use when building a design matrix, troubleshooting reversed fold-change direction, encoding paired or repeated-measures designs, detecting sample swaps, deciding sex-as-covariate, or aggregating technical replicates.

日本語の概要は準備中です。原文の説明を表示しています。

Handles batch effects in bulk RNA-seq via design-matrix inclusion (the correct path for DE), ComBat/ComBat-seq for visualization, SVA for unknown latent factors, RUVSeq for negative-control-gene-anchored unwanted variation, and limma::removeBatchEffect for plotting only. Encodes the Nygaard 2016 cardinal sin against testing on a batch-corrected matrix, the choice between SVA/RUVg/RUVs/RUVr, the confounding non-identifiability problem, the single-cell boundary (Harmony/MNN are NOT for bulk), and the Goh 2017 harmonization critique. Use when designing a DE analysis with batch structure, troubleshooting batch-dominated PCA, choosing ComBat vs ComBat-seq, handling unknown batch via SVA, integrating across studies, or deciding when (rarely) to subtract batch.

日本語の概要は準備中です。原文の説明を表示しています。

Build UpSet plots to visualize set intersections beyond 4 sets (where Venn fails) using ComplexUpset (modern, ggplot2-grammar) or the unmaintained UpSetR, with explicit cardinality vs degree sorting, attribute panels, and query highlighting. Use when comparing overlap across many gene sets, peak sets, variant lists, or any set membership matrix where Venn diagrams become illegible.

日本語の概要は準備中です。原文の説明を表示しています。

Detects acquired antimicrobial-resistance determinants and chromosomal point-mutation resistance in bacterial assemblies using AMRFinderPlus, ResFinder 4.0 (acquired + PointFinder), CARD-RGI, abritAMR, staramr, and species-specific callers (TB-Profiler, Mykrobe). Harmonises cross-tool output via hAMRonization, contextualises determinants with mobile-genetic-element annotation (MOB-suite, PlasmidFinder, MobileElementFinder, ICEberg), predicts phenotype against EUCAST or CLSI breakpoints, and translates calls into WHO GLASS reporting categories. Use when screening clinical or surveillance isolates for AMR, distinguishing acquired vs intrinsic vs point-mutation resistance, calling rpoB / katG / pncA / gyrA / mgrB mutations, reconciling AMRFinderPlus vs RGI vs ResFinder disagreement, contextualising carbapenemases or mcr alleles on plasmids, predicting susceptibility from genotype against the WHO Mtb 2nd-edition catalogue, or building a hAMRonized multi-lab AMR surveillance pipeline.

日本語の概要は準備中です。原文の説明を表示しています。

This skill directs lifelong treatment of cardiovascular risk factors, osteoporosis, and psychiatric symptoms in all patients with Cushing's syndrome until biochemical resolution of hypercortisolism. Use when managing any CS patient for long‑term comorbidity control; triggers include persistent hypertension, dyslipidemia, low bone density, depression, anxiety, or cognitive changes in the setting of known or suspected CS.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends bilateral adrenalectomy for occult or metastatic ectopic ACTH secretion or as a life-preserving emergency treatment in patients with very severe ACTH‑dependent Cushing’s syndrome who cannot be promptly controlled by medical therapy. It is triggered by life‑threatening complications of uncontrolled hypercortisolism such as infection, pulmonary thromboembolism, cardiovascular catastrophe, or acute psychosis.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends urgent treatment (within 24–72 hours) of hypercortisolism when life‑threatening complications of Cushing's syndrome such as infection, pulmonary thromboembolism, cardiovascular events, or acute psychosis are present. Trigger phrases include sepsis, PE, chest pain with hemodynamic instability, new‑onset psychosis, or delirium in a patient with known or suspected Cushing's.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating intravenous isotonic saline hydration as initial management for hypercalcemia of malignancy (HCM) while awaiting antiresorptive therapy, with fluid rate adjusted according to cardiac function. Triggered when a clinician encounters a patient with HCM (e.g., serum calcium >12 mg/dL, symptoms of hypercalcemia) and seeks immediate measures before specific drugs are available.

日本語の概要は準備中です。原文の説明を表示しています。

Work a primary-prevention patient through the 2026 ACC/AHA multisociety dyslipidaemia guideline CPR framework — Calculate (10-year and 30-year PREVENT-ASCVD), Classify (low / borderline / intermediate / high), Personalize (demographic, clinical, biomarker, and reproductive risk enhancers), and Reclassify (coronary artery calcium scoring where appropriate). Use when a clinician asks how to assess ASCVD risk for primary prevention, who needs a statin, borderline risk patient what to do, intermediate risk should I start a statin, risk enhancers to look for, premature family history of ASCVD how does it change risk, pregnancy-related risk factors, PCOS and cardiovascular risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate the Maryland Aggregate Pathology Index (MAPI) on a deceased donor procurement kidney biopsy to predict graft survival and decide single vs dual vs discard allocation. Trigger when a clinician asks "what's the MAPI score", "interpret donor kidney biopsy", "should I use this marginal kidney", "MAPI cutoff for transplant", "procurement biopsy scoring", or has histology results from a deceased donor kidney and needs an objective grading.

日本語の概要は準備中です。原文の説明を表示しています。

Teaches AI patients about stress-dosing and emergency glucocorticoid administration; instructs to obtain emergency card/bracelet/necklace and kit with injectable high-dose GC. Triggers when counseling any patient with adrenal insufficiency (e.g., "Use when counseling patient with adrenal insufficiency...").

日本語の概要は準備中です。原文の説明を表示しています。

Look up NHS England genomic tests for rare and inherited diseases. Use this skill whenever a clinician asks what genetic test to order for a condition, which genes are covered for a specific diagnosis, what commissioning category a genomic test falls under (Core, Specialised, or Highly Specialised), or which tests belong to a specialty group (Neurology, Cardiology, Endocrinology, etc.). Also trigger for questions like what panel is used for a condition, whether there is an NHS test for something, what the R number is for a condition, or whether anything has changed in the genomic test directory. Source: NHS England National Genomic Test Directory for Rare and Inherited Disease v9.0 (April 2026).

日本語の概要は準備中です。原文の説明を表示しています。

Decide when to order coronary artery calcium (CAC) scoring in a primary-prevention patient and interpret the result per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 indication (men ≥40 / women ≥45, borderline / intermediate PREVENT-ASCVD risk, uncertainty about LLT), CAC score interpretation (0, 1–99, 100–299, ≥300, ≥1000), how CAC modifies LDL and non-HDL goals, when to repeat CAC, and pitfalls (incidental CAC on non-cardiac CT, radiation, cost). Use when a clinician asks should I order a CAC score, CAC indications, what does CAC 150 mean, treatment goals with CAC score, repeat CAC frequency, CAC in a smoker, CAC vs CCTA, is CAC useful in intermediate risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Guides comorbidity-stratified selection of initial and further glucose-lowering medicines for adults with type 2 diabetes using the NICE NG28 (2026) framework, covering six clinical profiles: no relevant comorbidity, heart failure, atherosclerotic cardiovascular disease, early onset, obesity, chronic kidney disease, and frailty.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician asks what the 10-year ASCVD risk is, how to calculate PREVENT, PCE vs PREVENT, risk category for this patient, does my patient need a statin, 30-year risk calculation, primary prevention risk assessment. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends using the lowest tolerable hydrocortisone dose to potentially decrease risks of metabolic and cardiovascular disease in central adrenal insufficiency. Triggers include managing a patient with central adrenal insufficiency requiring glucocorticoid replacement.

日本語の概要は準備中です。原文の説明を表示しています。

Autonomous experiment loop that optimizes any file by a measurable metric. Inspired by Karpathy's autoresearch. The agent edits a target file, runs a fixed evaluation, keeps improvements (git commit), discards failures (git reset), and loops indefinitely. Use when: user wants to optimize code speed, reduce bundle/image size, improve test pass rate, optimize prompts, improve content quality (headlines, copy, CTR), or run any measurable improvement loop. Requires: a target file, an evaluation command that outputs a metric, and a git repo.

日本語の概要は準備中です。原文の説明を表示しています。

Marc Andreessen-mode decision and productivity skill. A blunt, market-first operator that pressure-tests ideas, ventures, features, and career bets through Andreessen's actual frameworks — market dominates team and product; the only milestone that matters is product/market fit; bias to build over deliberate. Use when the user says 'andreessen', 'pmarca mode', 'should I build this', 'is there a market', 'are we at product/market fit', 'pmf check', 'pressure-test this idea', 'be brutal about this venture', 'market-first take', or wants a no-disclaimers, no-hedging, confidence-leveled verdict on whether something is worth pursuing. Also provides the 3x5-card + Anti-Todo personal productivity routine. Runs on a fixed anti-sycophancy operating prompt: leads with the strongest counterargument, never validates premises, uses explicit confidence levels, never apologizes for disagreeing. Not for polite brainstorming — this skill exists to tell you the market is dead when it is.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive REST API design review with automated linting, breaking-change detection, and design scorecards. Catches inconsistent conventions, missing versioning, and design smells before APIs ship. Use when reviewing a PR that adds or changes API endpoints, auditing an existing API for v2 migration, or establishing API standards for a team.

日本語の概要は準備中です。原文の説明を表示しています。

Build bilingual, evidence-backed, SIEGER v2 customer intelligence reports for foreign-trade leads. Use when OpenClaw or a sales operator needs claim-level citations, decision gates, an industry-specific analysis lens, a non-fabricated verdict card, and sales angles that require approval before downstream outreach drafting.

日本語の概要は準備中です。原文の説明を表示しています。